Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.
News|Videos|May 25, 2023
Changing the Paradigms of How We Think About Depression
Author(s)Greg Mattingly, MD
Check out this review of the 2023 APA Annual Meeting presentation on the efficacy and safety of repeat treatment courses using novel medicine, zuranolone.
Advertisement
CONFERENCE REPORTER
Greg Mattingly, MD, shares a review of the 2023 APA Annual Meeting presentation that covered long term results of the year long study on zuranolone in major depressive disorder.
Dr Mattingly is an associate clinical professor at Washington University School of Medicine, and is a physician and principal investigator in clinical trials for Midwest Research Group.
Advertisement
Related to this article
Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
How tuning body signals with closed-loop sound and chill tech may ease dissociation and anhedonia, offering drug-free add-ons to therapy.
Phase 2 MOONLIGHT-1 shows JNJ-5120/PIPE-307 misses day‑5 MADRS improvement in MDD, yet remains well tolerated as J&J reviews next steps.
Experts dissect 10 common antidepressant myths, separating evidence from fear on efficacy, addiction, suicide risk, withdrawal, and safe tapering.
Health Canada has authorized a 200-participant phase 2 trial testing a single psilocybin dose for major depressive disorder, with dosing set to begin in 2027.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Adolescent Brain and Schizophrenia: What Research Reveals About Pruning, Dopamine, and Myelin
2
FDA Grants Breakthrough Device Designation to NET Recovery's Device for Stimulant Use Disorder
3
The Top 7 Atypical Psychedelics: A Brief Clinical Guide
4
Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
5